Gutiérrez-Igual S, Lucas-Domínguez R, Martí Rodrigo A, Romero Crespo I, Montesinos Mezquita MC. [New tools for medication review: DRP in patients treatment with proton pump inhibitors].
Aten Primaria 2024;
56:102836. [PMID:
38150850 PMCID:
PMC11058877 DOI:
10.1016/j.aprim.2023.102836]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/09/2023] [Accepted: 11/13/2023] [Indexed: 12/29/2023] Open
Abstract
OBJECTIVE
To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
DESIGN
Descriptive and retrospective observational study.
MATERIAL AND METHODS
The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
RESULTS
The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
CONCLUSIONS
The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.
Collapse